Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Radical Gastrectomy for Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient should be diagnosed as gastric cancer by pathology and have received radical gastrectomy. They should finish the following radiotherapy and chemotherapy and the treatment for surgical complications (such as leak, stricture, and marginal ulcer).~* Patient should be constitution of spleen qi deficiency, that is, meet two primary symptoms of spleen deficiency + two primary symptoms of qi deficiency, or meet two primary symptoms of spleen deficiency + one primary symptoms of qi deficiency + one auxiliary symptoms, or meet one primary symptoms of spleen deficiency + one primary symptoms of qi deficiency + two secondary symptoms + one auxiliary symptoms as follow:~  1. Main symptoms of spleen deficiency: a) poor appetite; b) abnormal stool (loose, diarrhea); c) abdominal distention after meal or afternoon~ 2. Main symptoms of qi deficiency: a) fatigue; b) tired mind and taciturnity~ 3. Secondary symptoms: a) tastelessness, hypodipsia, like hot drink, polysialia; b) abdominal pain, as a result either patients like warm or press, or remit after meal, or occur when work; c) nausea and vomiting; d) fullness in stomach; e) abnormal bowel sounds; f) lean or puffiness; g) sallow complexion; h) powerless defecation weakness; i) edema~ 4. Auxiliary symptoms: pale or swollen or teeth-printed tongue with thin and white fur~* Age ranges from 18 to 70 years; both male and female~* Patient should be in fair performance status, indicated by a score of Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1~* Sign the informed consent~Exclusion Criteria:~* Stage IV gastric cancer according to the Japanese classification criteria \[16\]~* Impaired liver function (total bilirubin \> 2 × upper limit of normal (ULN), alanine transaminase \> 2 × ULN, or aspartate aminotransferase \> 2 × ULN), kidney function (serum creatinine \> 2 × ULN), or hematopoiesis (neutrophil counts \< 0.5×109/L or, thrombocyte counts \< 20×109/L or, absolute reticulocyte counts \< 15×109/L)~* Obviously abnormal electrocardiogram~* Severe mental disorders~* Other severe diseases (e.g. multiple organ failure, HIV infection)~* Pregnant or breast-feeding women~* Allergic to the test sample~* Unwilling to provider personal information and sign the informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Hou Gu Mi Xi (Type: EXPERIMENTAL): Patients in this arm receive Hou Gu Mi Xi, with an oral dose of 10 g/day during entire follow up period (2 years).
- placebo (Type: PLACEBO_COMPARATOR): Patients in this arm receive placebo, with an oral dose of 10 g/day during entire follow up period (2 years).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues